Journey Medical Corp. (DERM)

Several events have impacted Journey Medical Corp.'s stock price in the past six months, including the release of Third Quarter 2025 and Full-Year 2025 financial results and the publication of clinical trial results for Emrosi. In March 2026, the stock price decreased by 44% for the month due to pressure on its Accutane franchise and other legacy products. However, the successful launch and strong prescription volume of Emrosi have been significant positive drivers, contributing to revenue growth and improved gross margins. The company achieved positive adjusted EBITDA in the fourth quarter of 2025 and anticipates remaining adjusted EBITDA positive in 2026 and the foreseeable future. The company also plans to launch one or two additional dermatology products later in 2026.

There are periods of higher and lower demand within the dermatology market, which would likely affect Journey Medical's product sales. The exact timing and magnitude of these seasonal fluctuations are not specified in the available information.

Journey Medical Corporation is a commercial-stage pharmaceutical company focused on developing and commercializing pharmaceutical products for dermatological conditions in the United States. The company's product portfolio includes FDA-approved prescription drugs such as Qbrexza, Accutane, Amzeeq, Zilxi, Emrosi, Exelderm, Targadox, and Luxamend.

Journey Medical Corporation's primary geographic focus is the United States, with its headquarters in Scottsdale, Arizona. It maintains 35 sales territories across the United States, covering approximately 80% of the top 50 metropolitan statistical areas (MSAs). In March 2026, the company also mentioned new out-licensing deals in Asia, indicating an expansion of its reach beyond the U.S.

Journey Medical's brand reputation has been positively influenced by the successful commercial launch and rapid uptake of Emrosi. Physician feedback for Emrosi has been very positive, and rising refill rates indicate patient satisfaction. The publication of Emrosi's Phase 3 clinical trial results in the Journal of Drugs in Dermatology in December 2025 and in JAMA Dermatology in March 2025 further bolstered the company's scientific credibility and product reputation. While generic competition has impacted sales of legacy products like Accutane, this is more of a market challenge than a direct hit to the company's overall brand reputation for quality or ethical practices.

Journey Medical Corporation has a diverse ownership structure, with 40.62% held by institutional shareholders, 31.12% by insiders, and 28.26% by retail investors. Major institutional owners include Tang Capital Management Llc, Wasatch Advisors Inc, Opaleye Management Inc., J. Goldman & Co LP, Vanguard Group Inc, BlackRock, Inc., Millennium Management Llc, Pale Fire Capital SE, Summit Financial, LLC, and Essex Investment Management Co Llc. Fortress Biotech, Inc. is a significant institutional holder, owning 15.15% of the company's shares. Key individual insiders with significant ownership include Claude Maraoui and Ramsey Alloush.